
Opinion|Videos|January 13, 2025
Main Conference Takeaways Regarding cGVHD Management
Author(s)Sergio A. Giralt, MD
Sergio A. Giralt, MD, discusses the key results from recent chronic graft-vs-host disease (cGVHD) research presented at ASH 2024 and how these findings will influence his clinical practice. He also shares his main takeaways on evolving strategies for cGVHD management.
Advertisement
Video content above is prompted by the following:
- What were the key results seen in this abstract and will they carry over to your clinical practice?
- What were your main takeaways with regard to chronic graft-vs-host disease management from ASH 2024?
Advertisement
Related to this article

Each additional hour of nightly CPAP use was associated with 13% lower all-cause mortality risk in a French cohort of adults with sleep apnea.

A 20-year Danish registry study found higher antidepressant and anxiolytic use among women with endometriosis, both before and after diagnosis.

AI-assisted spirometry, imaging biomarkers, and population screening strategies highlighted early detection and prevention as a throughline at the ERS Congress.

Ultimately, causality could not be established due to lack of data on disease severity and socioeconomic status, among others.

GRADE meta-analysis: hepatitis A vaccine blocks 96% in pre-exposure vaccination; outbreak response uses millions of doses, but post-exposure prophylaxis evidence is weak.

Alcohol abuse was the strongest post-trauma psychiatric predictor of cardiovascular events, with mood disorders more prominent among women.
Advertisement
Advertisement
Trending on AJMC
1
FDA Expands Finerenone Approval to CKD Associated With Type 1 Diabetes
2
Twice-Yearly CD19 Therapy Targets MG Root Cause: Richard Nowak, MD, MS
3
GLP-1 Receptor Agonists Cut Ascites, Mortality in MASH
4
Hepatitis A Vaccine Prevents 96% of Infections Given Before Exposure
5


